Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.

Memorial Sloan Kettering Cancer Center, New York

Our Lady of Mercy Medical Center, Comprehensive Cancer Center, The Bronx

University of Pennsylvania, Philadelphia

Georgetown University Medical Center, Lombardi Cancer Center, Washington D.C.

Washington Cancer Institute, Washington D.C.

Virginia Cancer Institute, Richmond

East Carolina University School of Medicine/ Division of Hematology/Oncology, Greenville

Cancer Centers of the Carolinas, Greenville

Vanderbilt University Medical Center, Nashville

Germantown Cancer Center, Germantown

Consultants in Blood Disorders and Cancer, Louisville

Hematology /Oncology Consultants Inc., Columbus

The Cleveland Clinic Foundation, Cleveland

Gabrail Cancer Center, Canton

Oncology Hematology Care Inc., Cincinnati

Cancer Care Center, Bloomington

Roger Maris Health System, Fargo

Oncology Specialists, S.C., Park Ridge

Northwestern University, Feinberg School of Medicine, Chicago

Rush Cancer Institute, Chicago

Arch Medical Group, LLC, St Louis

Kansas City Oncology and Hematology Group, Kansas City

Louisiana Health Sciences Center, Department of Medicine, Hematology/Oncology, Shreveport

Cancer Specialists of South Texas, P.A., Corpus Christi

ACRC/Arizona Clinical Research Center, Inc., Tucson

John Wayne Cancer Institute, Santa Monica

California Cancer Medical Center, West Covina

Hoag Cancer Center, Newport Beach

UC Davis Cancer Center, Sacramento

Oregon Heath and Science University, Portland

Division of Hematology/Oncology, University of Miami School of Medicine, Miami

Stanford University Medical Center, Stanford

Dartmouth-Hitchcock-Medical Center, Lebanon